FPF
HRTX icon

FNY Partners Fund’s Heron Therapeutics HRTX Stock Holding History

FNY Partners Fund’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		$40K Buy
+1,463
New +$33.2K 0.02% 196

Other funds holding HRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FNY Partners Fund's HRTX Position: Q1 2018 in Review

FNY Partners Fund opened a new position in Heron Therapeutics (HRTX) in Q1 2018: 1,463 shares worth $40K. The stake represents 0.02% of the portfolio and ranks #196 among its holdings.

152 funds tracked by Wall St. Rank hold HRTX as of Q1 2018.

  • FNY Partners Fund held 1,463 shares of Heron Therapeutics worth $40K as of Q1 2018.
  • Heron Therapeutics was a new FNY Partners Fund position in Q1 2018.
  • Heron Therapeutics made up 0.02% of FNY Partners Fund's portfolio in Q1 2018, its #196 holding.
  • 152 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2018.

Based on FNY Partners Fund's 13F filing for Q1 2018, filed 18 Apr 2018.